MOH describes its moratorium on new clinical research centres (CRCs) as a "proactive step" to bolster research capacity. MOH says not every hospital hosting a CRC is equipped for extensive clinical trials, hence a moratorium optimises existing resources.
MOH imposes a moratorium on new clinical research centres (CRCs), due to constraints in financial and HR resources for CRCs competing with clinical services. The Galen Centre says this may reduce Malaysia's FDI from new clinical trials by pharma companies.
Last year, infectious diseases topped new sponsored clinical research in Malaysia, reversing the trend since 2012 when oncology comprised the majority of studies, involving novel therapies.
Dr Voon Pei Jye from Sarawak General Hospital notes that there are very limited Malaysian Phase One oncology clinical trials published in international journals from 2011 to 2020.